AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37207924 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 2604
Study 37207924 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 2604
Study 37207923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid transcatheter edge-to-edge repair with the TriClip system (Abbott)
Number of subjects: 0
Study 37208019 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized multi-modal pre-habilitation algorithm and ERAS pathway
Number of subjects: 414
Study 37208019 — intervention group
Group type: COMPARATOR
Intervention: Historic control group
Number of subjects: 414
Study 37208019 — intervention group
Group type: COMPARATOR
Intervention: Prospective control group
Number of subjects: 414
Study 37208019 — intervention group
Group type: COMPARATOR
Intervention: Health insurance controls
Number of subjects: 414
Study 37208126 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 50
Study 37208126 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 37208131 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP measured preoperatively
Number of subjects: 431
Study 37208131 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP categories based on conversion from NT-pro-BNP categories
Number of subjects: 431
Study 37208131 — intervention group
Group type: COMPARATOR
Intervention: NT-pro-BNP values predicted by an existing formula
Number of subjects: 431
Study 37208131 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin measurements on postoperative days 1, 2, and 3
Number of subjects: 431
Study 37208131 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of MINS and vascular death
Number of subjects: 431
Study 37208132 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality exposure treatment system (P-ARET)
Number of subjects: 0
Study 37208132 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure treatment (IVET)
Number of subjects: 0
Study 37208132 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 0
Study 37208132 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ARET
Number of subjects: 0
Study 37208132 — intervention group
Group type: EXPERIMENTAL
Intervention: IVET
Number of subjects: 0
Study 37208132 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 0
Study 37208133 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7 (333 µg/day)
Number of subjects: 450
Study 37208133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 37208135 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy
Number of subjects: 1700
Study 37208135 — intervention group
Group type: COMPARATOR
Intervention: Transrectal prostate biopsy
Number of subjects: 1700
Study 37208138 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) assessment
Number of subjects: 139
Study 37208142 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection-based AR exposure therapy with multiple stimuli (P-ARET MS)
Number of subjects: 80
Study 37208142 — intervention group
Group type: COMPARATOR
Intervention: Projection-based AR exposure therapy with a single stimulus (P-ARET SS)
Number of subjects: 80
Study 37208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through interviews or focus groups
Number of subjects: 0
Study 37208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data collection of self-reported demographic characteristics
Number of subjects: 0
Study 37208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of orientation tools and educational materials
Number of subjects: 0
Study 37208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesis of values and perspectives of patients and family members
Number of subjects: 0
Study 37208187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal swab (OPS)
Number of subjects: 23102
Study 37208187 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal swab (NPS)
Number of subjects: 23102
Study 37208187 — intervention group
Group type: COMPARATOR
Intervention: Saliva specimen
Number of subjects: 23102
Study 37208282 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Number of subjects: 2916
Study 37208282 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 2916
Study 37208431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose 7.5 mg/kg
Number of subjects: 35
Study 37208431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose 15 mg/kg
Number of subjects: 35
Study 37208512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 36
Study 37208512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 36
Study 37208556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib + hyper-CVAD
Number of subjects: 2
Study 37208556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib + steroids
Number of subjects: 2
Study 37208556 — intervention group
Group type: COMPARATOR
Intervention: Imatinib + hyper-CVAD
Number of subjects: 2
Study 37208556 — intervention group
Group type: COMPARATOR
Intervention: Imatinib monotherapy induction + imatinib-containing consolidation
Number of subjects: 2
Study 37208654 — intervention group
Group type: COMPARATOR
Intervention: Initial measurements (no intervention)
Number of subjects: 52
Study 37208654 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 8 years
Number of subjects: 52
Study 37208674 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized corneal crosslinking (cCXL)
Number of subjects: 0
Study 37208674 — intervention group
Group type: COMPARATOR
Intervention: Standard corneal crosslinking (sCXL)
Number of subjects: 0
Study 37208675 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lidocaine with epinephrine 1:200,000
Number of subjects: 66
Study 37208675 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 2% lidocaine with epinephrine 1:200,000 plus 2 mL sodium bicarbonate 4.2% (total of 12 mL)
Number of subjects: 66
Study 37208687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in PrEP provider
Number of subjects: 451
Study 37208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet NIV
Number of subjects: 80
Study 37208787 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal oxygen
Number of subjects: 80
Study 37208787 — intervention group
Group type: COMPARATOR
Intervention: Intubated patients
Number of subjects: 80
Study 37208998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg, once daily
Number of subjects: 5795
Study 37208998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5795
Study 37209152 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg unfractionated heparin (UFH)
Number of subjects: 25
Study 37209152 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg unfractionated heparin (UFH)
Number of subjects: 25
Study 37209152 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg enoxaparin
Number of subjects: 25
Study 37209152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoxaparin
Number of subjects: 25
Study 37209152 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study 37209201 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure and empathic communication (intervention group)
Number of subjects: 250
Study 37209201 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 250
Study 37209238 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 60
Study 37209238 — intervention group
Group type: COMPARATOR
Intervention: Interferon/ribavirin (prior treatment)
Number of subjects: 60
Study 37209243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous computerized anaesthesia (ICA) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Number of subjects: 72
Study 37209243 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Number of subjects: 72
Study 37209422 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based training in exposure therapy
Number of subjects: 13
Study 37209422 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 13
Study 37209422 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral health setting
Number of subjects: 13
Study 37209421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment support via free combination NRT at discharge and automated counseling
Number of subjects: 321
Study 37209421 — intervention group
Group type: COMPARATOR
Intervention: Usual care (quitline-based approach)
Number of subjects: 321
Study 37209421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment support
Number of subjects: 321
Study 37209427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront 25 mg
Number of subjects: 16
Study 37209427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront 50 mg
Number of subjects: 16
Study 37209427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 37209700 — intervention group
Group type: EXPERIMENTAL
Intervention: AAd5 (0.1 mL)
Number of subjects: 360
Study 37209700 — intervention group
Group type: EXPERIMENTAL
Intervention: IMAd5 (0.3 mL)
Number of subjects: 360
Study 37209700 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine (BBIBP-CorV or CoronaVac; 0.5 mL)
Number of subjects: 360
Study 37209779 — intervention group
Group type: EXPERIMENTAL
Intervention: Modernized collaborative care for depression
Number of subjects: 216
Study 37209779 — intervention group
Group type: COMPARATOR
Intervention: Standard care for depression
Number of subjects: 216
Study 37209893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine balloon tamponade combined with sulprostone infusion
Number of subjects: 403
Study 37209893 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine balloon tamponade after sulprostone infusion
Number of subjects: 403
Study 37209934 — intervention group
Group type: EXPERIMENTAL
Intervention: miWe wheelchair simulator (simulator group)
Number of subjects: 47
Study 37209934 — intervention group
Group type: COMPARATOR
Intervention: kart driving videogame (control group)
Number of subjects: 47
Study 37209934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 37209996 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloons (DCBs)
Number of subjects: 40
Study 37209996 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balloons
Number of subjects: 40
Study 37210041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies with optimal anti-infective prophylaxis
Number of subjects: 93
Study 37210041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies in women with PID
Number of subjects: 93
Study 37210041 — intervention group
Group type: EXPERIMENTAL
Intervention: History of severe infection
Number of subjects: 93
Study 37210041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes in women with PID
Number of subjects: 93
Study 37210048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART), 50 gray in 5 fractions.
Number of subjects: 136
Study 37210075 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT program with advance notification 'primers' (live calls and texts) and automated reminders
Number of subjects: 70
Study 37210075 — intervention group
Group type: EXPERIMENTAL
Intervention: Live phone primers
Number of subjects: 70
Study 37210075 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notifications sent by text
Number of subjects: 70
Study 37210075 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 70
Study 37210075 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT program
Number of subjects: 70
Study 37210072 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC) combined with energy restriction recommendations (ROC+)
Number of subjects: 129
Study 37210072 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 129
Study 37210098 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg rimegepant
Number of subjects: 1431
Study 37210098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study 37210099 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (≤80 mg, as tolerated)
Number of subjects: 128
Study 37210099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 37210099 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine
Number of subjects: 128
Study 37210220 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA coupling (TAPSE/PASP ratio <0.39)
Number of subjects: 404
Study 37210220 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA uncoupling (TAPSE/PASP ratio >0.39)
Number of subjects: 404
Study 37210220 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA coupling
Number of subjects: 404
Study 37210220 — intervention group
Group type: COMPARATOR
Intervention: No RVD
Number of subjects: 404
Study 37210220 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA uncoupling after TAVI
Number of subjects: 404
Study 37210308 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1388 25 μg
Number of subjects: 60
Study 37210308 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1388 50 μg
Number of subjects: 60
Study 37210308 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1388 100 μg
Number of subjects: 60
Study 37210308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37210308 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1388 (all doses)
Number of subjects: 60
Study 37210308 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1388 (50 μg and 100 μg)
Number of subjects: 60
Study 37210516 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 254
Study 37210516 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 254
Study 37210543 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 162
Study 37210608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1209
Study 37210741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of 5-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0
Study 37210741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 5-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0
Study 37210741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 25-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0
Study 37210741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37210742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 61
Study 37210742 — intervention group
Group type: COMPARATOR
Intervention: Metolazone 5-10 mg once daily
Number of subjects: 61
Study 37210742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 61
Study 37210742 — intervention group
Group type: COMPARATOR
Intervention: Metolazone
Number of subjects: 61
Study 37210887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy plus a Memory Support Intervention
Number of subjects: 178
Study 37210887 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy as usual
Number of subjects: 178
Study 37211138 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry-derived perilesional sensitivity
Number of subjects: 67
Study 37211138 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 67
Study 37211138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-vision Cambridge Color Test
Number of subjects: 67
Study 37211138 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field electroretinography (ERG)
Number of subjects: 67
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective repair
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Truly untreated status
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptures among truly untreated women
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality among truly untreated women
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for nonintervention
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility for endovascular repair
Number of subjects: 200
Study 37211143 — intervention group
Group type: EXPERIMENTAL
Intervention: 55-mm threshold analysis
Number of subjects: 200
Study 37211146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 0
Study 37211155 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine access in Massachusetts Wave 2 HCS communities
Number of subjects: 0
Study 37211155 — intervention group
Group type: EXPERIMENTAL
Intervention: E2SFCA index scores
Number of subjects: 0
Study 37211155 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related incidents
Number of subjects: 0
Study 37211155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural communities' access to buprenorphine prescribers
Number of subjects: 0
Study 37211155 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburban communities' opioid-related incidents
Number of subjects: 0
Study 37211246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 36
Study 37211246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 36
Study 37211246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 37211246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg and 30 mg
Number of subjects: 36
Study 37211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive for glaucoma or suspected glaucoma
Number of subjects: 1171
Study 37211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1171
Study 37211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying as Black/African-American
Number of subjects: 1171
Study 37211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an established eyecare clinician
Number of subjects: 1171
Study 37211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Not driving a personal vehicle to the appointment
Number of subjects: 1171
Study 37211338 — intervention group
Group type: COMPARATOR
Intervention: ADI comparison
Number of subjects: 1171
Study 37211338 — intervention group
Group type: COMPARATOR
Intervention: White participants at FQHC vs. free clinic
Number of subjects: 1171
Study 37211338 — intervention group
Group type: COMPARATOR
Intervention: ADI comparison for White participants
Number of subjects: 1171
Study 37211611 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent exercise program with weekly telephone supervision from diagnosis until three months post-surgery
Number of subjects: 250
Study 37211611 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 250
Study 37211764 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction
Number of subjects: 20
Study 37211764 — intervention group
Group type: COMPARATOR
Intervention: Open suction
Number of subjects: 20
Study 37211798 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for family nursing students
Number of subjects: 69
Study 37211798 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study 37211832 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (N=68)
Number of subjects: 136
Study 37211832 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (N=68)
Number of subjects: 136
Study 37211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions during cord blood transplant (CBT)
Number of subjects: 10
Study 37211950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 162
Study 37211963 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted intervention
Number of subjects: 22
Study 37211967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular gain-framed letter
Number of subjects: 65075
Study 37211967 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated letter at day 14
Number of subjects: 65075
Study 37211967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65075
Study 37211977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11007
Study 37211977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11007
Study 37212068 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Non-Invasive Ventilation (NIV) initiation (FVC below 75%)
Number of subjects: 42
Study 37212068 — intervention group
Group type: COMPARATOR
Intervention: Standard Non-Invasive Ventilation (NIV) initiation (FVC below 50%)
Number of subjects: 42
Study 37212116 — intervention group
Group type: EXPERIMENTAL
Intervention: GrimAge clock markers
Number of subjects: 45
Study 37212116 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAmTL
Number of subjects: 45
Study 37212116 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychiatric Inventory severity scores
Number of subjects: 45
Study 37212168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 654
Study 37212168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 37212312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk sexual contacts of mpox patients
Number of subjects: 25
Study 37212312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk nonsexual contacts of mpox patients
Number of subjects: 25
Study 37212312 — intervention group
Group type: EXPERIMENTAL
Intervention: Presymptomatic phase of infection
Number of subjects: 25